Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to offer a novel cancer vaccine called poly-ICLC (Hiltonol®) for
subjects with malignant pleural mesothelioma by directly injecting the vaccine into the
tumor.
This trial will enroll a maximum of 18 patients with biopsy proven malignant pleural
mesothelioma who are surgically resectable. Subjects will undergo core biopsies of their
mesothelioma followed by direct injection of Poly ICLC, a TLR3 agonist which has been shown
to have biological and immunological effects. Within two to three weeks following the
injection, the patients will undergo a pleurectomy/decortication or EPP, as is standard of
care. Tissue resected at that time will be compared to tissue obtained at biopsy prior to the
injection of the immunological agent.